268 related articles for article (PubMed ID: 31210949)
1. Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D.
Singh P; Silvester J; Chen X; Xu H; Sawhney V; Rangan V; Iturrino J; Nee J; Duerksen DR; Lembo A
United European Gastroenterol J; 2019 Jun; 7(5):709-715. PubMed ID: 31210949
[TBL] [Abstract][Full Text] [Related]
2. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes.
Dunlop SP; Hebden J; Campbell E; Naesdal J; Olbe L; Perkins AC; Spiller RC
Am J Gastroenterol; 2006 Jun; 101(6):1288-94. PubMed ID: 16771951
[TBL] [Abstract][Full Text] [Related]
3. Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis.
Gecse K; Róka R; Séra T; Rosztóczy A; Annaházi A; Izbéki F; Nagy F; Molnár T; Szepes Z; Pávics L; Bueno L; Wittmann T
Digestion; 2012; 85(1):40-6. PubMed ID: 22179430
[TBL] [Abstract][Full Text] [Related]
4. Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies.
Basseri RJ; Kunkel D; Low K; Conklin JL; Pimentel M
J Clin Gastroenterol; 2011 Oct; 45(9):790-3. PubMed ID: 21301356
[TBL] [Abstract][Full Text] [Related]
5. Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits.
Miwa J; Echizen H; Matsueda K; Umeda N
Digestion; 2001; 63(3):188-94. PubMed ID: 11351146
[TBL] [Abstract][Full Text] [Related]
6. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.
Halmos EP; Power VA; Shepherd SJ; Gibson PR; Muir JG
Gastroenterology; 2014 Jan; 146(1):67-75.e5. PubMed ID: 24076059
[TBL] [Abstract][Full Text] [Related]
7. [Serum serotonin concentration and urine 5-hydroxyindole acetic acid excretion in patients with irritable bowel syndrome].
Moskwa A; Chojnacki J; Wiśiewska-Jarosińska M; Stec-Michalska K; Szadkowski K; Smigielski J; Chojnacki C
Pol Merkur Lekarski; 2007 May; 22(131):366-8. PubMed ID: 17679369
[TBL] [Abstract][Full Text] [Related]
8. [Changes of tight junction claudin-1,-3,-4 protein expression in the intestinal mucosa in patients with irritable bowel syndrome].
Kong WM; Gong J; Dong L; Xu JR
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep; 27(9):1345-7. PubMed ID: 17884774
[TBL] [Abstract][Full Text] [Related]
9. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.
Martínez C; Lobo B; Pigrau M; Ramos L; González-Castro AM; Alonso C; Guilarte M; Guilá M; de Torres I; Azpiroz F; Santos J; Vicario M
Gut; 2013 Aug; 62(8):1160-8. PubMed ID: 22637702
[TBL] [Abstract][Full Text] [Related]
10. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype.
Bertiaux-Vandaële N; Youmba SB; Belmonte L; Lecleire S; Antonietti M; Gourcerol G; Leroi AM; Déchelotte P; Ménard JF; Ducrotté P; Coëffier M
Am J Gastroenterol; 2011 Dec; 106(12):2165-73. PubMed ID: 22008894
[TBL] [Abstract][Full Text] [Related]
11. Postprandial platelet-poor plasma 5-hydroxytryptamine concentrations during diarrhea and constipation periods of alternatingtype irritable bowel syndrome patients.
Sen F; Pinarbaşi B; Işsever H; Akyüz F; Mungan Z; Kaymakoğlu S
Turk J Gastroenterol; 2011 Jun; 22(3):270-8. PubMed ID: 21805417
[TBL] [Abstract][Full Text] [Related]
12. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations.
Martínez C; Vicario M; Ramos L; Lobo B; Mosquera JL; Alonso C; Sánchez A; Guilarte M; Antolín M; de Torres I; González-Castro AM; Pigrau M; Saperas E; Azpiroz F; Santos J
Am J Gastroenterol; 2012 May; 107(5):736-46. PubMed ID: 22415197
[TBL] [Abstract][Full Text] [Related]
13. Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of alternating and diarrhea predominant IBS.
Wilcz-Villega E; McClean S; O'Sullivan M
Neurogastroenterol Motil; 2014 Mar; 26(3):316-25. PubMed ID: 24286617
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome.
Róka R; Rosztóczy A; Leveque M; Izbéki F; Nagy F; Molnár T; Lonovics J; Garcia-Villar R; Fioramonti J; Wittmann T; Bueno L
Clin Gastroenterol Hepatol; 2007 May; 5(5):550-5. PubMed ID: 17336590
[TBL] [Abstract][Full Text] [Related]
15. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients.
Rana SV; Sharma S; Sinha SK; Parsad KK; Malik A; Singh K
Trop Gastroenterol; 2012; 33(4):251-6. PubMed ID: 23923350
[TBL] [Abstract][Full Text] [Related]
16. Discriminant and convergent validity of the GSRS-IBS symptom severity measure for irritable bowel syndrome: A population study.
Ljótsson B; Jones M; Talley NJ; Kjellström L; Agréus L; Andreasson A
United European Gastroenterol J; 2020 Apr; 8(3):284-292. PubMed ID: 32213021
[TBL] [Abstract][Full Text] [Related]
17. Endocrine cells in the ileum of patients with irritable bowel syndrome.
El-Salhy M; Gilja OH; Gundersen D; Hatlebakk JG; Hausken T
World J Gastroenterol; 2014 Mar; 20(9):2383-91. PubMed ID: 24605036
[TBL] [Abstract][Full Text] [Related]
18. Expression of G protein-coupled estrogen receptor in irritable bowel syndrome and its clinical significance.
Qin B; Dong L; Guo X; Jiang J; He Y; Wang X; Li L; Zhao J
Int J Clin Exp Pathol; 2014; 7(5):2238-46. PubMed ID: 24966932
[TBL] [Abstract][Full Text] [Related]
19. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.
Cremon C; Carini G; Wang B; Vasina V; Cogliandro RF; De Giorgio R; Stanghellini V; Grundy D; Tonini M; De Ponti F; Corinaldesi R; Barbara G
Am J Gastroenterol; 2011 Jul; 106(7):1290-8. PubMed ID: 21427712
[TBL] [Abstract][Full Text] [Related]
20. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
